Blog

Dr. Mitchell Hayes received a 2024 Kidney Cancer Association Trailblazer Award in partnership with the Michael and Ina Korek Foundation for research on "Tracing the Seeds of Progression: Spatial Transcriptomic Analysis of Immunoresistant Kidney Cancer". Dr. Hayes is a Urologic Oncology Fellow at Moffitt Cancer Center in Tampa, Florida. We spoke with Dr. Hayes about his research and the impact…

Dr. Elizabeth Ellis received a 2024 Kidney Cancer Association Chromophobe RCC Focus Award in partnership with the Chromophobe and Oncocytic Tumor Alliance for research on "Evaluating the Response of Chromophobe Renal Cell Carcinoma to Novel Targeted Metabolic Therapies". Dr. Ellis is a Urologic Oncology Fellow at MD Anderson Cancer Center in Houston, Texas. We spoke with Dr. Ellis about her…

The Kidney Cancer Association (KCA) awarded five grants to investigators pursuing high-impact kidney cancer research across a variety of focus areas through its annual KCA Award Program. Each $75,000 award supports early- to mid-career investigators whose projects align with topics that require greater attention and understanding from researchers, doctors, and patients. In total, the KCA distributed $375,000 in research funds.…

We rounded up a few research highlights from the 2024 Congress of the European Society for Medical Oncology (ESMO), held recently in Madrid, Spain. Belzutifan continues to outperform targeted therapy in advanced kidney cancer Belzutifan outperformed targeted therapy with everolimus in certain advanced kidney cancer patients, who experienced longer times till their tumors began growing again with the novel hypoxia-inducible factor 2a…

People with metastatic kidney cancer who already received one or two lines of treatment that included immunotherapy did not fare better when offered an additional round of immunotherapy after their cancer progressed. The results from the phase 3 TiNivo-2 trial, presented at the recent European Society of Medical Oncology (ESMO) meeting in Barcelona, Spain, compared combination treatment with the targeted…

This is a guest post by Jeffrey Ellin, 45, who has a rare genetic BAP1 mutation that puts him at high risk for developing multiple cancers, including kidney cancer, which he was diagnosed with in 2023. Jeff is based in Baltimore, Maryland. Discovering I Was at Risk Jeff Ellin after completing the 2024 Marine Corp Marathon on October 27, 2024.…

The Metastatic Brain Tumor Collaborative (MBTC), created by the American Brain Tumor Association (ABTA), announced a request for applications for one-year, $50,000 research grants. Faculty – including early-career faculty – are encouraged to apply.  Applicants should propose high-risk, high-impact research projects that will improve the understanding of brain metastasis and have the potential to change current diagnostic or treatment paradigms…

The 2024 International Kidney Cancer Symposium (IKCS): North America, taking place in Louisville, Kentucky on November 7-9, will feature three special awards recognizing outstanding leaders in kidney cancer. Register now. Dr. Daniel J. George Dr. Daniel J. George will receive the Nicholas J. Vogelzang Humanitarian Award for his service to kidney cancer patients and his contributions to kidney cancer care,…

NEW YORK, NY and HOUSTON, TX — The Cancer Research Institute (CRI) is proud to announce a new collaboration with the Kidney Cancer Association (KCA) to fund a CRI  Clinic & Laboratory Integration Program (CLIP) investigator specifically for immunologists and cancer researchers who are pursuing innovative kidney cancer research. CLIP grants are designed to support preclinical and translational research aimed at optimizing cancer immunotherapy…

This is a guest post by Liam Piscetelli, the KCA’s 2024 Research Intern. Liam Piscetelli For the past 8 months, I have interned with the KCA as a research intern. As a student working towards their Masters of Public Health with a concentration in Applied Epidemiology from the University of Arizona, this opportunity to work with the KCA proved to…